Trametinib (Mekinist)

Indications

  • Metastatic Melanoma with BRAF V600E Gene Mutation (see Melanoma, [[Melanoma]]): used in combination with the BRAF inhibitor Dabrafenib (Tafinlar) (see Dabrafenib, [[Dabrafenib]]), due to resistance to Dabrafenib which develops within 6-7 mo
    • FDA approved for this indication May 30, 2013

Pharmacology

  • MEK Inhibitor

Administration

  • xxx

Adverse Effects

Other Adverse Effects

  • xxxx

References

  • xxx